Metabolic FingerPrinting (MetaPrint)

March 30, 2022 updated by: Arcensus GmbH
The MetaPrint study aims to characterize the metabolic fingerprint of genetic diseases in order to enhance knowledge on the physiological disease status and establish so new tools for diagnosing, monitoring and personalizing treatment of genetic diseases.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Albania
      • Tirana, Albania, 1000
        • Recruiting
        • University Hospital Center Mother Teresa
        • Contact:
          • Paskal Cullufi, Prof.
  • Pakistan
      • Islamabad, Pakistan, 4485
        • Recruiting
        • Pakistan Institute of Medical Sciences (PIMS)
        • Contact:
          • Maqbool Hussain, Prof.
      • Multan, Pakistan, 60000
        • Recruiting
        • Children's Hospital & The Institute of Child Health
        • Contact:
          • Nuzhat Rana, Prof.
      • Peshawar, Pakistan, 25100
        • Recruiting
        • Khyber institute of Child Health and Children Hospital (KICH)
        • Contact:
          • Khalil Rehman, Dr.
    • Punjab
      • Lahore, Punjab, Pakistan, 54000
        • Recruiting
        • The Children's Hospital & Institute of Child Health
        • Contact:
          • Huma Cheema, Prof.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

2 months and older (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All subjects with a confirmed genetic disease as well as their first degree family members can participate in the study.

Description

Inclusion Criteria:

  • Informed consent is obtained from the participant or from the parent/ legal guardian
  • The participant is 2 months or older
  • The participant is diagnosed with a genetic disease
  • The participant is a first degree relative of a subject diagnosed with a genetic disease

Exclusion Criteria:

  • Informed consent is not obtained from the participant or from the parent/ legal guardian
  • The participant is younger than 2 months
  • The participant is not diagnosed with a genetic disease
  • The participant is not a first degree relative of a subject diagnosed with a genetic disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Subjects with a genetic disease
Other: No intervention
No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of newly identified, disease-specific Metabolic Fingerprints
Time Frame: 5 years
Plasma-derived metabolite profiles that are specific for a particular genetic disease in comparison to healthy controls and other genetic diseases
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Arcensus GmbH

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 1, 2021

Primary Completion (ANTICIPATED)

March 1, 2026

Study Completion (ANTICIPATED)

March 1, 2026

Study Registration Dates

First Submitted

March 21, 2022

First Submitted That Met QC Criteria

March 30, 2022

First Posted (ACTUAL)

March 31, 2022

Study Record Updates

Last Update Posted (ACTUAL)

March 31, 2022

Last Update Submitted That Met QC Criteria

March 30, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MetaPrint-2021

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Sharing of IPDs can be discussed after receiving scientific requests.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Genetic Disease

Clinical Trials on No intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe